Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activ...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Coutre, Steven, Choi, Michael, Furman, Richard R., Eradat, Herbert, Heffner, Leonard, Jones, Jeffrey A., Chyla, Brenda, Zhou, Lang, Agarwal, Suresh, Waskiewicz, Tina, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Wierda, William G., Davids, Matthew S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Clinical Trials And Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922273/
https://ncbi.nlm.nih.gov/pubmed/29305552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-788133
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items